Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

Research & Clinical Trials
Toggle Menu

NCT01853306

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib in Subjects With Solid Tumors

Study identifier: NCT01853306
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Metastatic or unresectable breast or ovarian cancer for which standard curative measures do not exist or are no longer effective (platinum-resistant ovarian cancer not permitted)
  • Must have documented deleterious BRCA1 or BRCA2 mutation
  • Three or fewer cytotoxic chemotherapy regimens

Type of study:

Phase I study

Treatment:

Participants are treated with one of three formulations of veliparib

Study sites:

Contact for all sites is:

Contact: Brian Oliver, BS 847-938-5570 brian.oliver@abbvie.com
Contact: Xenia Kovacs, BS 847-938-4057 xenia.kovacs@abbvie.com

Arizona
Scottsdale
Site Reference ID/Investigator# 89594

Michigan
Detroit
Site Reference ID/Investigator# 89593

New Jersey
Hackensack
Site Reference ID/Investigator# 89834

New Brunswick
Site Reference ID/Investigator# 89595

Utah
Salt Lake City
Site Reference ID/Investigator# 89596

Page updated 06/13/13